VILINBIO (VILINBIO) fundamentals
VILINBIO is a listed company, part of the Pharmaceuticals sector, listed on the NSE as VILINBIO (ISIN INE0L4V01013). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What VILINBIO does
Vilin Bio Med Limited is an India-based company engaged in the business of manufacturing and selling pharmaceutical products. The Company is engaged in the manufacturing of pharmaceutical formulations, such as oral liquids, dry syrups, sachets, external preparations, beta and non-beta lactam tablets and capsules and nutritional food supplements. Its products include cardiovascular drugs, musculoskeletal drugs, antibiotic drugs, central nervous system drugs, alimentary system drugs, genitourinary tract drugs, respiratory system and anti-allergic drugs, anti-diabetic drugs, multi-vitamins, minerals and amino acids supplements, miscellaneous drugs, liquid orals and external preparations. Its cardiovascular drugs include ATORVOSTATIN + Aspirin Capsules, Dapagliflozin 10 milligrams (mg) tablets, Fluvastatin Tablets 40 mg, PRASUGREL 10 mg tablets, and Cilnidipine five mg tablets. Its external preparations include calamine lotion, ciprofloxacin, fluocinolone acetonide and others.
Valuation and market data
| Last close | ₹58.95 |
|---|---|
| Market capitalisation | ₹81 crore |
| Enterprise value | ₹81 crore |
| P/E (TTM) | 36.17 |
| Price to book | 3.52 |
| Price to sales (TTM) | 1.50 |
| Book value per share | ₹16.77 |
| Dividend yield | 0.00% |
| Sector | Pharmaceuticals |
| Industry | — |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹42 crore | ₹3 crore | ₹2 crore | 0.00 |
| Mar 2025 | ₹15 crore | ₹0 crore | ₹0 crore | 0.16 |
| Mar 2024 | ₹16 crore | ₹0 crore | ₹0 crore | 0.12 |
| Mar 2023 | ₹12 crore | ₹2 crore | ₹1 crore | 1.25 |
| Mar 2022 | ₹11 crore | ₹0 crore | ₹0 crore | 0.10 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 56.6% |
|---|---|
| Foreign institutions (FII) | 0.0% |
| Mutual funds | 0.0% |
| Other domestic institutions | 0.0% |
| Retail and others | 43.4% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.